Serena Pescuma

Dr. Serena Pescuma

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
PPPier Mario Perrone
Pier Mario Perrone
ICIlaria Casolaro
Ilaria Casolaro
SPSerena Pescuma
Serena Pescuma
IBIlaria Bruno
Ilaria Bruno
MCMartina Cappellina
Martina Cappellina
SCSilvana Castaldi
Silvana Castaldi
Background/Objectives: Human papillomavirus (HPV) infection is a major concern in public health, given its role as a persistent sexually transmitted infection and a causative agent of non-cancerous and cancerous lesions (neoplasms). The increasing infection rates observed in recent years underscore the need for effective public health measures to address this issue. The objective of this study is to describe the challenges and the results of conducting vaccination campaigns within a university setting and its impact on the HPV vaccination rate. Methods: A multifaceted approach was adopted, entailing the implementation of two distinct interventions. Following the promotional and educational online campaign (described elsewhere), vaccination delivery took place from November 2024 to July 2025 in the university campus and in three university hospitals in Milan. Overall and covariate-specific drop-out rate is calculated; significance is tested through a chi-square test of homogeneity between the population that completed less than three doses vs. those who completed the full cycle. Overall and vaccine-specific vaccination proportion is reported. Results: The vaccination rate for first doses reached 92% of available appointments, with a slight female majority (50.9%) and the 23–26 age as the most represented group (47%). The most represented nationality was Italian (58.4%), followed by Iranian (26.5%). Regarding the vaccination sites, the university venue recorded the highest rates in terms of both vaccines booked (56.4%) and vaccines administered (64.7%). With a net loss in follow up, consistent with WHO data, the three-dose HPV vaccination campaign was completed by 82.5% of participants. A chi-squared test of homogeneity revealed significant differences in age distribution between vaccination groups, χ2 (3) = 347.78, p < 0.001, Cramér’s V = 0.457. Participants who received only one dose were predominantly younger (17–22 years: 71.1% vs. 19.0%, difference = 52.1 percentage points, 95% CI [46.6, 57.7]). Meanwhile, a catch-up strategy raised interest on other crucial vaccinations. Conclusions: The findings pertaining to the vaccination rate underscore the heightened awareness among young adults concerning the HPV vaccine. They further substantiate the efficacy of the integrated strategy encompassing advisory and educational site-based campaigns as an initial measure to attain the WHO-endorsed vaccination rates.